Lataa...

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncogene
Päätekijät: Yang, H, Kircher, D A, Kim, K H, Grossmann, A H, VanBrocklin, M W, Holmen, S L, Robinson, J P
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2017
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/
https://ncbi.nlm.nih.gov/pubmed/28263969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!